Oxford Biomedica Expands U.S. Presence With North Carolina Facility Acquisition

Oxford Biomedica (LON: OXB) has expanded its U.S. manufacturing footprint with the acquisition of a commercial-scale viral vector facility in Durham, North Carolina, from National Resilience Holdco Inc. subsidiary RTP Operating LLC.

The FDA-approved site adds large-scale GMP manufacturing and fill-finish capabilities, strengthening OXB’s position as a global cell and gene therapy contract development and manufacturing organisation (CDMO).

The deal, valued at $4.5 million (£3.4 million) and funded through existing cash, aligns with OXB’s strategy to add U.S. capacity to meet rising client demand.

Integration planning is said to be underway, with key functions expected to be operational by early 2026.

Chief Executive Dr. Frank Mathias called the acquisition “a major milestone in OXB’s evolution as a global, innovation-led CDMO partner of choice.”

He said the North Carolina site “significantly expands our footprint in the world’s largest cell and gene therapy market” and enhances OXB’s ability to serve clients “across all major viral vector types and stages of development, particularly those in the AAV field.”

The new facility, located in the Research Triangle Park biopharma hub, includes two GMP drug substance suites, a dedicated fill-finish suite, and on-site quality control labs, with room for future expansion.

It complements OXB’s existing network in Oxford, Lyon, Strasbourg, and Bedford, Massachusetts, with the Bedford site remaining an AAV centre of excellence for early-stage development.

OXB expects the acquisition to support top-line growth and EBITDA profitability from fiscal 2025, while keeping its financial guidance unchanged and maintaining investment plans consistent with its August 2025 strategy update.